Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
MUMBAI, India and PRINCETON, N.J., March 27, 2026 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced it will present 14 abstracts during the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 27-31, 2026, in Denver, Colorado. The data reinforce the company's expertise across dermatology and immunology and its commitment to safe, effective medications for psoriasis, alopecia areata and acne.“The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice,” said Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer, Sun Pharma.
Notable presentations include data evaluating ILUMYA® (tildrakizumab-asmn) which included a Phase 3b study in moderate-to-severe psoriasis affecting the nails showing sustained efficacy and safety over 52 weeks. Pooled data from THRIVE-AA1 and THRIVE-AA2 pivotal trials of LEQSELVI™ (deuruxolitinib) in severe alopecia areata demonstrated significant scalp hair regrowth as early as Week 8 and Week 12. An open-label study evaluating WINLEVI ® (clascoterone cream 1%) demonstrated significant and progressive reduction in casual facial sebum production and acne severity.
Sun Pharmaceutical Industries Limited will offer engagement opportunities for clinicians at its booth exhibit (Booth #2915).
| Abstract Titles | INVESTIGATOR(S) | Abstract Number |
|---|---|---|
| ILUMYA (TILDRAKIZUMAB): PLAQUE PSORIASIS | ILUMYA (TILDRAKIZUMAB): PLAQUE PSORIASIS | ILUMYA (TILDRAKIZUMAB): PLAQUE PSORIASIS |
| Real-World Tildrakizumab Effectiveness in the US by Biologic Experience and Geographic Region in the PPD ™ CorEvitas ™ Psoriasis Registry | Lockshin B, Beeghly A, et al | Poster Podium # 71091 Presentation on March 27 @2:40-2:45 PM |
| Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial | Yamauchi P, Kerdel F, et al | Poster Podium # 74582 Presentation on March 28 @8:35-8:40 AM |
| Real-World Tildrakizumab Persistence in the US by Biologic Experience and Insurance Coverage in the PPD CorEvitas Psoriasis Registry | Lockshin B, Beeghly A, et al | Poster # 73014 |
| Regional Differences in Patient Characteristics Among US Biologic Initiators from the PPD CorEvitas Psoriasis Registry | Prajapati V, Blachley T, et al | Poster # 73017 |
| Sustained effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study* | Augustin M, et al | Poster # 71092 |
| Beyond skin clearance: Tildrakizumab improves high burdensome symptoms and psychological well-being in moderate-to- severe psoriasis patients - 2-year POSITIVE study results* | Mrowietz U, et al | Poster # 75192 |
| LEQSELVI (DEURUXOLITINIB): ALOPECIA AREATA | LEQSELVI (DEURUXOLITINIB): ALOPECIA AREATA | LEQSELVI (DEURUXOLITINIB): ALOPECIA AREATA |
| Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials | Mostaghimi A, Senna MM, et al | Poster Podium # 74582 Presentation on March 27 @9:35-9:40 AM |
| Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials | Mesinkovska NA, Mostaghimi A, et al | Poster # 74643 |
| Efficacy of deuruxolitinib across subgroups of patients with severe alopecia areata by demographic and baseline characteristics: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials | Senna MM, King B, et al | Poster # 74609 |
| Landmark survey of clinician perspectives, preferences, and challenges in the care of alopecia areata | Mesinkovska NA, Mostaghimi A, et al | Poster # 74665 |
| Landmark survey of patient and clinician perspectives on the impact and treatment priorities in alopecia areata | Mesinkovska NA, Mostaghimi A, et al | Poster # 74686 |
| WINLEVI (CLASCOTERONECREAM 1%): ACNE | WINLEVI (CLASCOTERONECREAM 1%): ACNE | WINLEVI (CLASCOTERONECREAM 1%): ACNE |
| Reduction in facial sebum production following treatment with clascoterone cream 1% for 52 weeks in patients with acne vulgaris | Draelos ZD, et al | Poster #73913 |
| Efficacy and safety of combination treatment with clascoterone cream 1% and clindamycin 1.2%/benzoyl peroxide 5% gel for 16 weeks in patients with acne | Kircik L, et al | Poster # 73022 |
| Efficacy and safety of combination treatment with clascoterone cream 1% and adapalene gel 0.3% for 16 weeks in patients with acne | Kircik L, et al | Poster # 73019 |
ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis. LEQSELVI (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata. WINLEVI (clascoterone) cream 1% is indicated for the topical treatment of acne vulgaris.
Sun Pharmaceutical Industries Limited is a leading specialty generics company.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Last edited by a moderator: